{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"The area under the plasma concentration-time curve (AUC; measured in ng\\*hr/mL) is a method of measurement to determine the total exposure of a drug in blood plasma. The AUC24 of elotuzumab was to be estimated using non-compartmental methods and data reported as the mean ± standard deviation. No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated due to sparse serum concentration collections.","groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally in Phase 1.","id":"OG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally in Phase 1 and Phase 2.","id":"OG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally in Phase 1 and Phase 2.","id":"OG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone"}],"populationDescription":"No noncompartmental pharmacokinetic parameters (e.g., AUC, CL, V, t 1/2) were estimated (collected data not reliable due to assay limitations caused by sparse serum concentrations).","reportingStatus":"POSTED","timeFrame":"Cycle 1: Days 1, 8, and 15; Cycle 2: Days 1 and 22; Cycle 3 and beyond: Day 1","title":"Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of Elotuzumab","type":"SECONDARY"}